Methyl aminolevulinate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Methyl aminolevulinate
Methyl aminolevulinate.svg
Clinical data
AHFS/Drugs.comMultum Consumer Information
ATC code
CAS Number
PubChem CID
Chemical and physical data
Molar mass145.156 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Methyl aminolevulinate (MAL) is a drug used as a sensitizer in photodynamic therapy. It is a prodrug that is metabolized to protoporphyrin IX. It is marketed as Metvix.

Metvix cream is applied topically and some time later the skin is illuminated with a proprietary red light (630 nm) source (medical lamp 'Aktilite') to activate the photosensitiser.

Metvix is developed by Photocure and Galderma has bought all rights to Metvix.[1]

Approvals and indications[edit]

Interim result of phototherapy for actinic keratosis with Metvix one week after exposure. Patient has light skin and blue eyes.

Methyl aminolevulinate is approved in New Zealand for treatment of basal cell carcinoma.[2]

It is now approved in many countries and has been used to treat non-melanoma skin cancer (including basal cell carcinoma).[3]

It has some advantages over Levulan.[4]

It has been reported as controversial in some quarters, with severe pain allegedly being experienced by some patients. [5]


  1. ^ "Archived copy". Archived from the original on 2011-02-07. Retrieved 2010-09-10. Photocure divests Metvix to Galderma
  2. ^ "Methyl aminolevulinate photodynamic therapy (MAL PDT)"
  3. ^ "New 5 Year Metvix-PDT Data Demonstrate Long-Term Efficacy & Reliability For NM Skin Cancer Treatment" 2006
  4. ^[dead link] Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009 by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
  5. ^